GHRP-2
GHRP-2 is a peptide, indexed here under Growth hormone secretagogues.
Identity
| Field | Value |
|---|---|
| Classification | Peptide |
| Primary class | Growth hormone secretagogues |
| CAS registry number | 158861-67-7[1] |
| PubChem CID | 6918245[1] |
| UniProt accession | Unknown No UniProt query was run in v1. |
| Molecular formula | C45H55N9O6[1] |
| Molecular weight | 818 g/mol[1] |
| Amino-acid sequence | Unknown Not reported by the PubChem property set retrieved for this record; no sequence database query was run in v1. |
| Reported half-life | Unknown No pharmacokinetics source was retrieved in v1. PubChem does not carry half-life as a property, so this is recorded as not yet sourced rather than estimated. |
What the cited literature examines
GHRP-2, reported under the generic name pralmorelin, is a synthetic growth hormone-releasing peptide. A 1994 Journal of Endocrinology paper reports its effect on growth hormone secretion from primary cultured ovine pituitary cells, a 1996 paper in the same journal reports the effects of GHRP-6 and GHRP-2 on intracellular cyclic AMP levels, and a 1997 Peptides paper reports effects of GHRP-2 and hexarelin on growth hormone, prolactin, ACTH and cortisol levels.
Human endocrine records in the retrieved set include a 2002 Clinical Endocrinology paper on combined administration with TRH and GnRH to men with prolonged critical illness and a 2005 Journal of Clinical Endocrinology and Metabolism paper reporting that, like ghrelin, it increases food intake in healthy men. Two 2005 American Journal of Physiology papers report an anti-inflammatory effect and an effect on E3 ubiquitin-ligating enzymes in arthritic rats. Analytical records include a 2010 Drug Testing and Analysis paper identifying the compound in a nutritional supplement and a 2010 Rapid Communications in Mass Spectrometry paper on its determination in human urine.
[3, 4, 5, 6, 7, 8, 9, 10, 11]Reported mechanism
A synthetic growth hormone-releasing peptide described in the retrieved records as a ghrelin receptor agonist, with reported effects on growth hormone secretion and intracellular cyclic AMP.
[9, 4]Stated in the titles of the cited 2005 American Journal of Physiology and 1996 Journal of Endocrinology papers.
Targets named in the cited records: growth hormone secretagogue receptor.
FDA application register
A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.[2]
Scope statement: this records the result of a single automated query against the openFDA drugsfda endpoint on the stated date. It is not legal advice and is not a jurisdiction-by-jurisdiction legality assessment.
Retrieved 2026-10-09.
Amounts reported in the cited literature
Unknown. No retrieved record in this dataset states an amount, so none is shown. Where an amount is recorded it is what a named study reported administering in its own stated model, in the past tense, and is not a protocol.
No study-reported dose was taken from a source read in v1. Literature-reported values are only recorded where the retrieved citation metadata states the figure.
Adverse effects reported in the cited literature
Unknown. No retrieved record in this dataset reports an adverse effect for this compound, so no row is shown. Absence of a row records the absence of a retrieved report, nothing more.
No adverse-effect row was taken from a source read in v1. Rows are only recorded with the study model named and the reporting citation attached.
Other names
GHRP-2 appears under these other names in the cited records or in common usage. Each one resolves to this page rather than to a separate page of its own.
- pralmorelin
- growth hormone-releasing peptide-2
- KP 102
Where this page sits
Research records
Cited research records for GHRP-2, each with its identifier, the publication type it is indexed as, and the study model stated by its assigned subject headings.
Side-by-side pages that include GHRP-2
Compounds indexed next to it
- GHRP-6 — Growth hormone secretagogues
- Ipamorelin — Growth hormone secretagogues
Named targets in the cited records
Class page: Growth hormone secretagogues. Full index: all indexed compounds.
Questions this page answers
What does the cited literature examine for GHRP-2?
GHRP-2, reported under the generic name pralmorelin, is a synthetic growth hormone-releasing peptide. A 1994 Journal of Endocrinology paper reports its effect on growth hormone secretion from primary cultured ovine pituitary cells, a 1996 paper in the same journal reports the effects of GHRP-6 and GHRP-2 on intracellular cyclic AMP levels, and a 1997 Peptides paper reports effects of GHRP-2 and hexarelin on growth hormone, prolactin, ACTH and cortisol levels.
Which class is GHRP-2 indexed under?
GHRP-2 is indexed under Growth hormone secretagogues. Growth hormone secretagogues are compounds that act at the growth hormone secretagogue receptor, the receptor for ghrelin, rather than at the growth hormone releasing hormone receptor.
What does the FDA application register show for GHRP-2?
A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.
Sources
- PubChem Compound Summary for CID 6918245, Pralmorelin. PubChem, National Library of Medicine (2026). pubchem:6918245
- Drugs@FDA application register query for this compound, no application records returned. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:ghrp-2
- The effect of GH-releasing peptide-2 (GHRP-2 or KP 102) on GH secretion from primary cultured ovine pituitary cells can be abolished by a specific GH-releasing factor (GRF) receptor antagonist. The Journal of endocrinology (1994). pmid:8169551
- The effects of GH-releasing peptide-6 (GHRP-6) and GHRP-2 on intracellular adenosine 3',5'-monophosphate (cAMP) levels and GH secretion in ovine and rat somatotrophs. The Journal of endocrinology (1996). pmid:8699133
- Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. Comparison with the effects of GHRH, TRH and hCRH. Peptides (1997). pmid:9285939
- The combined administration of GH-releasing peptide-2 (GHRP-2), TRH and GnRH to men with prolonged critical illness evokes superior endocrine and metabolic effects compared to treatment with GHRP-2 alone. Clinical endocrinology (2002). pmid:12030918
- Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men. The Journal of clinical endocrinology and metabolism (2005). pmid:15699539
- Anti-inflammatory effect of the ghrelin agonist growth hormone-releasing peptide-2 (GHRP-2) in arthritic rats. American journal of physiology. Endocrinology and metabolism (2005). pmid:15507538
- Ghrelin receptor agonist GHRP-2 prevents arthritis-induced increase in E3 ubiquitin-ligating enzymes MuRF1 and MAFbx gene expression in skeletal muscle. American journal of physiology. Endocrinology and metabolism (2005). pmid:16030067
- Identification of the growth-hormone-releasing peptide-2 (GHRP-2) in a nutritional supplement. Drug testing and analysis (2010). pmid:20878896
- Determination of growth hormone secretagogue pralmorelin (GHRP-2) and its metabolite in human urine by liquid chromatography/electrospray ionization tandem mass spectrometry. Rapid communications in mass spectrometry : RCM (2010). pmid:20552695
On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.